Skip to main content

Table 1 Schedule of data collection

From: Peer support for the maintenance of physical activity and health in cancer survivors: the PEER trial - a study protocol of a randomised controlled trial

Assessment or Outcome

Study Period

Time Point:

Pre-FM

FM

Pre-SP

Post-SP

3 M

6 M

12 M

Screening

 Participant eligibility

✓

      

 Adult Pre-Exercise Screening System

✓

      

 Informed consent

✓

      

 Doctor’s consent

✓

      

 Medical history and current status

✓

✓

✓

✓

✓

✓

✓

 Demographics

✓

      

 Concomitant research study participation

✓

✓

✓

✓

✓

✓

✓

Primary Outcomes

 Moderate-to-vigorous physical activity (MVPA)

  

✓

✓

✓

✓

✓

Secondary Outcomes

 Cardiorespiratory fitness (\( \dot{\mathrm{V}}{\mathrm{O}}_{2\mathrm{peak}} \))

 

✓

✓

✓

✓

✓

✓

 Body composition (DXA)

  

✓

✓

✓

✓

✓

 Anthropometry (BMI)

  

✓

✓

✓

✓

✓

 Strength (isometric grip strength)

  

✓

✓

✓

✓

✓

 Blood biomarkers (IL-6, IL-8, Hepcidin, TNF-α, IGF-1, IGF-2, IGFBP-3 and CRP)

  

✓

✓

✓

✓

✓

 Self-reported physical activity (Godin)

  

✓

✓

✓

✓

✓

 Sedentary behaviour and light physical activity (accelerometry)

  

✓

✓

✓

✓

✓

 Quality of life and wellbeing (EORTC QLQ C-30, SF-36 and FACT-G)

  

✓

✓

✓

✓

✓

 Cancer-related fatigue (FACIT-F)

  

✓

✓

✓

✓

✓

 Insomnia (ISI)

  

✓

✓

✓

✓

✓

 Symptom distress (BSI)

  

✓

✓

✓

✓

✓

 Depression and anxiety (DASS, PHQ-9 and GAD-7)

  

✓

✓

✓

✓

✓

 Participant:peer supporter relationship (Therapeutic Alliance)

  

✓

✓

✓

✓

✓

 Self-efficacy

  

✓

✓

✓

✓

✓

 Barriers and enablers to PA

  

✓

✓

✓

✓

✓

Tertiary Outcomes

 Semi-structured interviews

      

✓

 Physical activity preferences

  

✓

✓

✓

✓

✓

 Economic evaluation (AQoL-8D)

  

✓

✓

✓

✓

✓

 Adverse and serious adverse events

 

✓

✓

✓

✓

✓

✓

  1. Key: Pre-FM pre-familiarisation, FM familiarisation, Pre-SP pre-supervised phase, Post-SP post-supervised phase, 3 M 3-months post-randomisation testing, 6 M 6-months post-randomisation testing, 12 M 12-months post-randomisation testing, \( \dot{\mathrm{V}}{\mathrm{O}}_{2\mathrm{peak}} \) peak volume of oxygen consumption, DXA dual energy X-ray absorptiometry, BMI body mass index, IL-6 interleukin 6, IL-8 interleukin 8, TNF-α tumour necrosis factor – alpha, IGF-1 insulin-like growth factor 1, IGF-2 insulin-like growth factor 2, IGFBP-3 insulin-like growth factor-binding protein 3, CRP C-reactive protein, Godin Godin Leisure-Time Physical Activity Questionnaire, EORTC QLQ C-30 European Organization for Research and Treatment of Cancer quality of life questionnaire for people with cancer, SF-36 Short form 36 health survey, FACT-G Functional Assessment of Cancer Therapy: General, FACIT-F The Functional Assessment of Chronic Illness Therapy: Fatigue, ISI Insomnia Severity Index, BSI Brief Symptom Inventory, DASS Depression Anxiety Stress Scale, PHQ-9 Patient Health Questionnaire-9, GAD-7 Generalised Anxiety Disorder 7-item scale, PA physical activity, AQoL-8D Assessment of Quality of Life – 8 Dimensions Multi-Attribute Utility Instrument